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EDITORIAL REVIEW
Treatment and prevention of hyperkalemia in end-stage renal
disease
Physiologic regulation of extrarenal potassium disposal
Rational treatment and prevention of hyperkalemia in pa-
tients with end-stage renal disease requires a thorough under-
standing of the physiologic regulation of potassium homeosta-
sis. There are two distinct homeostatic mechanisms for
potassium. The first maintains external potassium balance by
matching potassium excretion to dietary intake. The kidneys
normally excrete 90 to 95% of the total, with the remaining 5 to
10% excreted by the gut. Excretion of an acute potassium load
is a relatively slow process, such that only half the load is
excreted in the first four to six hours [1]. The second homeo-
static mechanism shifts potassium from the extracellular to the
intracellular fluid compartment. This process, referred to as
"extrarenal potassium disposal," is very rapid, occurring
within minutes of a potassium load. Total body potassium
(about 3500 mEq) is distributed unevenly, with about 98% of the
total in the intracellular fluid compartment (primarily in skeletal
muscle, and to a lesser extent in the liver) and 2% in the
extracellular fluid compartment [2]. Because of this uneven
distribution, relatively small shifts of potassium from the intra-
cellular to the extracellular fluid compartment can produce
severe hyperkalemia, and conversely, relatively small shifts of
potassium from the extracellular to the intracellular fluid com-
partments can produce a marked decrease in plasma potassium
concentration. In patients with end-stage renal disease, renal
excretion of potassium is negligible. As a result, extrarenal
potassium disposal assumes a critical role in the defense against
hyperkalemia.
A recent review [31 provided an excellent overview of extra-
renal potassium disposal in chronic renal failure and treatment
of acute hyperkalemia. The present review provides an exten-
sive update of experimental information obtained in the last two
years that enhances our understanding of mechanisms of extra-
renal potassium disposal. It also includes an in-depth discussion
of physiologic mechanisms that prevent hyperkalemia in dialy-
sis patients, as well as their clinical implications.
Regulation of the Na-K pump
The Na-K pump is a major determinant of extrarenal potas-
sium disposal. It is a ubiquitous membrane-bound system that
produces an influx of potassium and efflux of sodium [4].
Inhibition of the Na-K pump by ouabain results in an increase
in intracellular sodium, a decrease in intracellular potassium,
and a low resting membrane potential in erythrocytes and
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skeletal muscle cells. Clinically, substantial inhibition of the
Na-K pump, as occurs in digitalis poisoning, manifests with
severe hyperkalemia [5, 61. A number of factors can produce
either chronic or acute changes in the activity of the Na-K
pump. High dietary potassium intake, hyperthyroidism, and
physical training result in chronic up-regulation of the Na-K
pump; in contrast, potassium depletion and hypothyroidism
produce chronic down-regulation of the Na-K pump [4, 7].
Insulin and epinephrine are the two major physiologic factors
that promote acute changes in Na-K pump activity. Both
hormones stimulate in vitro Na-K pump activity in rat and frog
skeletal muscle [8—13]; these effects are specifically blocked by
ouabain. The stimulatory effects of insulin and epinephrine on
potassium influx into skeletal muscle fibers are additive, sug-
gesting that they are mediated by distinct signaling pathways
[14]. The effect of epinephrine is mediated by the beta-2
adrenergic receptor, blocked by propranolol, and mediated by
cAMP as the second messenger [8].
The mechanism by which insulin stimulates the Na-K pump
activity is not as well characterized. Unlike beta-adrenergic
activation, the stimulatory effect of insulin is not mediated by
cAMP [12]. Two recent studies documented insulin stimulation
of Na-K-ATPase activity in rat soleus muscle [15, 161. Since
insulin stimulates cellular Na/H exchange [17, 18], the accu-
mulation of intracellular sodium could secondarily stimulate the
Na-K pump. However, in isolated rat soleus muscle inhibition
of the Na-H antiporter by amiloride does not affect insulin-
induced potassium uptake, arguing against this indirect mech-
anism [16]. Because the stimulatory effect of insulin occurs
within minutes, it is not likely to be mediated by the synthesis
of additional sodium pumps. Two isoforms of the alpha-subunit
of the Na-K-ATPase have been identified: the a1 and a2
isoforms [19]. Skeletal muscle and adipocytes, the two cell
types richest in insulin receptors, possess primarily the a2
isoform of Na-K-ATPase [19, 20]. Insulin increases the affinity
of the a2 isoform for sodium [21]. Recent experimental evidence
suggests the presence of two Na-K pump pools: an active
(membrane-bound) poo1 and an inactive (intracellular) pool.
Insulin induces translocation of the a2 subunit from the intra-
cellular to the plasma membrane compartment [20], thereby
providing a mechanism for increasing Na-K-ATPase activ-
ity. Such a mechanism is analogous to the recruitment by
insulin of the glucose transporter from the intracellular to the
plasma membrane compartment in skeletal muscle [22].
Chronic renal failure is associated with an impairment of the
Na-K pump activity. Most of the experimental evidence has
been obtained in erythrocytes from uremic animals or patients.
Studies in uremic erythrocytes have typically found elevated
sodium concentrations, decreased rates of ouabain-inhibitable
potassium (or rubidium) influx and sodium efflux, decreased
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specific binding of ouabain, and decreased activity of the
Na-K-ATPase enzyme. These defects are corrected after sev-
eral weeks of dialysis [reviewed in 231. It is not clear whether
the observations in erythrocytes are representative of changes
in skeletal muscle cells. Erythrocytes are enucleate, and there-
fore lack the ability to synthesize additional Na pumps. More-
over, since Na-K activity decreases with increasing erythrocyte
age, the measured activity represents an average of cells with a
wide range of ages. Direct investigations of the changes in Na-K
pump activity in uremic skeletal muscle are more instructive. In
one of the few clinical studies to evaluate the effect of renal
failure on skeletal muscle Na-K activity, Cotton et al [24]
documented increased sodium concentration, decreased potas-
sium concentration, and decreased resting membrane potential
in skeletal muscle from uremic patients, as compared with
normal controls. Seven weeks of hemodialysis restored all
these physiologic parameters to normal. Recent studies in
soleus muscle from rats with experimental uremia, revealed a
significant decrease in ouabain-inhibitable rubidium uptake, as
compared with muscle from control rats [13]. Moreover, the
rate of rubidium uptake was inversely proportionate to serum
creatinine concentration [25]. The etiology of the defect in
Na-K pump in uremia is poorly characterized. A number of
factors have been proposed, including volume overload, meta-
bolic acidosis, endogenous ouabain-like substance, thyroxine
deficiency, and hyperparathyroidism [23].
The effect of uremia on insulin stimulation of the Na-K pump
in skeletal muscle has been investigated recently. In vitro
incubation with insulin stimulated ouabain-inhibitable rubidium
uptake to a greater degree in skeletal muscle from uremic rats,
as compared with muscle from control rats [13]. Given the
enhanced insulin sensitivity in uremic muscle, one might pre-
dict increased levels of the &2 (insulin-sensitive) isoform. How-
ever, Northern analysis has revealed a lower level of message
for the a2 isoform in uremic muscle as compared with normal
muscle [25]. This observation suggests a post-transcriptional
effect of uremia, perhaps manifested by enhanced insulin-
induced translocation of the a2 isoform from the intracellular
compartment to the plasma membrane. The effect of epineph-
rine on the Na-K pump in uremic skeletal muscle has not been
reported.
Effects of insulin on extrarenal potassium disposal
A number of elegant clinical studies have established the
effect of insulin on extrarenal potassium disposal in normal
humans. DeFronzo et al [26] administered insulin at various
infusion rates to a group of normal subjects; glucose was
infused at a rate that maintained normoglycemia. Infusion rates
producing steady-state plasma insulin concentrations in the
middle of the physiologic range (37 mU/liter) decreased plasma
potassium by about 0.5 mmol/liter. Insulin concentrations in the
upper physiologic range (100 mU/liter), comparable to those
achieved after an acute glucose load, resulted in a 1.0 mmol/liter
decrease in plasma potassium. At pharmacologic concentra-
tions of insulin (1200 mU/liter) there was a still greater decrease
in plasma potassium (1.5 mmol/liter). The stimulation of extra-
renal potassium disposal by insulin is independent of adrenergic
nervous system activation, as it is unaffected by beta-blockade
[27, 28].
The potassium-lowering effect of insulin is preserved in
patients with end-stage renal disease [29]. Continuous insulin
infusion at a rate that achieved a steady-state plasma insulin
concentration in the high physiologic range (about 100 mU!
liter), produced a similar magnitude of decrease in plasma
potassium in hemodialysis patients and normal controls (0.98
and 0.95 mmol/liter, respectively). Three subsequent clinical
studies have confirmed the efficacy of intravenous insulin
(administered either as a bolus or a continuous infusion) in
lowering plasma potassium in hyperkalemic dialysis patients;
the potassium lowering effect was evident within 15 minutes of
treatment. In these three studies plasma potassium decreased
by a mean of 0.6 to 1.0 mmollliter after one hour [30—32].
It is well established that dialysis patients are resistant to the
glucose-lowering action of insulin [33—35]. This is in contrast to
the preserved potassium lowering effect of insulin in uremia.
Intra-arterial insulin infusion enhances skeletal muscle uptake
of potassium and glucose in the human forearm; concurrent
ouabain infusion blocks the cellular uptake of potassium, but
not glucose [36]. These observations suggests that insulin
stimulates cellular glucose and potassium uptake by two dis-
tinct signaling pathways, and that uremia results in a postrecep-
tor defect that selectively affects the glucose transport pathway,
and manifests as "insulin resistance."
Since glucose predictably stimulates endogenous insulin se-
cretion in nondiabetic individuals, the administration of dex-
trose alone may be efficacious in acutely lowering plasma
potassium in dialysis patients. The use of dextrose without
insulin in this clinical setting is unwise for two reasons. First,
the pharmacologic concentration of insulin required to achieve
a maximal decrease in plasma potassium cannot be achieved
after a glucose load [26]. More importantly, the administration
of hypertonic dextrose alone may produce paradoxic hyperka-
lemia in patients without adequate insulin reserve. Thus, Vib-
erti et al [37] observed an acute decrease in plasma potassium in
nondiabetic individuals receiving a 100 g oral glucose load. The
same load given to Type I diabetics resulted in a significant
increase in plasma potassium. A hyperkalemic response to
acute glucose administration in insulin-dependent diabetics has
also been reported by other investigators [38—40]. The hyper-
kalemic effect of hyperglycemia is due to hyperosmolality;
similar effects have been observed in dialysis patients when the
osmolality is raised acutely by infusion of mannitol, hypertonic
saline, and hypertonic arginine [41—43].
Effect of catecholamines on extrarenal potassium disposal
The potassium lowering effect of epinephrine has been rec-
ognized for nearly 60 years. D'Silva [44] first reported that
intravenous epinephrine in cats produced a transient increase in
serum potassium, followed by a sustained decrease. The acute
potassium-lowering effect of epinephrine has been confirmed by
numerous subsequent animal and human studies [45—51]. Sev-
eral lines of evidence suggest that this potassium lowering effect
is mediated by beta-2 receptors. First, isoproterenol and pre-
nalterol, two relatively selective beta-i agonists, do not lower
serum potassium levels, in contrast to epinephrine, a nonselec-
tive beta agonist [47, 52]. Second, the administration of the
selective beta-2 antagonist, ICI- 118551, or the nonselective beta
blocker, timolol, prevents the potassium lowering effect of
epinephrine [47, 49, 53]. In contrast, beta-i selective blockers,
such as atenolol, do not prevent epinephrine-induced reduction
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in plasma potassium [53]. Third, selective beta-2 agonists, such
as albuterol and fenoterol, decrease plasma potassium in nor-
mal subjects [54—56].
The aipha-adrenergic system has the opposite effect on
extrarenal potassium disposal: it causes potassium to shift from
the intracellular to the extracellular compartment. A number of
studies have suggested that the alpha-adrenergic system is
physiologically important in the regulation of extrarenal potas-
sium disposal. The alpha-blocker, prazosin, augments the po-
tassium lowering effect of albuterol in dogs [57]. The adminis-
tration of the alpha-agonist, phenylephrine, during potassium
administration to normal humans, augments the rise in serum
potassium; this effect is blocked by the concomitant adminis-
tration of the alpha-blocker, phentolamine [58]. Moreover, the
alpha-blocker phentolamine, attenuates exercise-induced hy-
perkalemia [59].
The reproducible observation of reduction in plasma potas-
sium after administration of beta-2 agonists to normal individ-
uals suggests the utility of these agents for the acute treatment
of hyperkalemia in patients with end-stage renal disease. Mon-
toliu, Lens and Revert [60] reported that a 0.5 mg intravenous
dose of albuterol acutely decreased plasma potassium by a
mean of 1.1 mmol/liter in hyperkalemic patients with acute or
chronic renal failure. This salutory effect occurred within 30
minutes, and was sustained for up to six hours. In most patients
the electrocardiographic abnormalities associated with hy-
perkalemia improved or resolved after treatment with albuterol
alone, in the absence of calcium, bicarbonate, insulin, dextrose,
or potassium exchange resins. Although albuterol administra-
tion increased plasma insulin levels significantly, the potassium-
lowering effect was independent of the effect on insulin. Mur-
doch, Dos Anjos and Haycock [61] administered intravenous
albuterol to 13 children with hyperkalemia in the setting of
acute or chronic renal failure, and observed a mean decrease of
1.5 mmol/liter in plasma potassium; the effect was sustained for
at least two hours. The potassium-lowering effect of intrave-
nous albuterol is additive to that of insulin [32].
Beta-2 agonists in nebulized form have a substantial potas-
sium lowering effect in normal subjects, suggesting significant
systemic absorption of the inhaled drug [55, 56, 62, 63]. Allon,
Dunlay and Copkney [64] demonstrated that nebulized a!-
buterol was useful for the acute treatment of hyperkalemia in
hemodialysis patients. Plasma potassium was decreased by a
mean of 0.6 mmol/liter after a 10 mg dose and by 1.0 mmollliter
after a 20 mg dose. The potassium lowering effect of albuterol
was evident within 30 minutes, and lasted for at least two hours.
A similar potassium lowering effect was observed in diabetic
and nondiabetic patients. The albuterol dose required to lower
plasma potassium was four- to eightfold higher than that used
for the treatment of asthma. Presumably, only a small fraction
of inhaled albuterol is absorbed into the systemic circulation,
and only that fraction stimulates extrarenal potassium disposal.
The efficacy of nebulized albuterol in the acute treatment of
hyperkalemia was confirmed in two subsequent studies [30, 65].
The use of albuterol in critically ill patients with acute renal
failure or in hemodialysis patients likely to have a high inci-
dence of coronary artery disease has the potential to produce
serious adverse effects. Nevertheless, studies utilizing intrave-
nous or nebulized albuterol for the acute treatment of hyperka-
lemia have uniformly found this therapeutic modality to be
well-tolerated. In six hyperkalemic children with acute renal
failure after cardiac surgery, intravenous albuterol did not affect
the heart rate, blood pressure or arterial oxygen saturation [61].
In four studies evaluating the effect of nebulized and intrave-
nous albuterol in chronic adult hemodialysis patients, the mean
increase in heart rate varied between 8 and 20 beats per minute
[30, 32, 60, 64]. Tremor has been reported in a minority of
patients receiving albuterol. A modest increase in plasma
glucose (about 2 to 3 mmol/liter) has been observed after both
intravenous or nebulized albuterol, but this seems to be of little
clinical consequence [30, 32, 60, 64]. Thus, albuterol therapy is
both efficacious and safe for the acute treatment of hyperkale-
mia in patients with renal failure.
Allon and Copkney [30] compared the potassium-lowering
effects of nebulized albuterol and intravenous insulin in hemo-
dialysis patients. Insulin-plus-dextrose and nebulized albuterol
were equally effective in lowering plasma potassium. The onset
of action of insulin occurred within 15 minutes, and that of
nebulized albuterol was seen at 30 minutes. Moreover, the two
drugs had an additive potassium lowering effect (Fig. 1). The
administration of insulin with dextrose resulted in a transient
hyperglycemia at 15 minutes, with a return to normoglycemia at
30 minutes. However, between 30 and 60 minutes after insulin
administration the patients developed significant hypoglycemia,
with a plasma glucose less than 3 mmollliter in 9 of 12 patients.
Albuterol alone resulted in a significant increase in plasma
glucose over the 60-minute study period, presumably by stim-
ulating gluconeogenesis [66]. Administration of albuterol along
with insulin-plus-dextrose prevented the late hypoglycemia
(Fig. 2), with a plasma glucose less than 3 mmol/liter observed
in only 2 of 10 patients. Thus, the addition of albuterol to insulin
therapy not only produces an additive potassium lowering
effect, but also protects against insulin-induced hypoglycemia.
In contrast to the predictable potassium-lowering action of
epinephrine in normal subjects, a number of studies have
observed a resistance to this effect in dialysis patients [31, 50,
51, 67]. Gifford et al [51] observed a 0.4 mmol/liter decrease in
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Fig. 1. Changes in plasma potassium after treatment with insulin +
glucose (solid squares), albuterol (open circles), and insulin + glucose
+ albuterol (solid circles), * P < 0.001 vs. baseline value + P < 0.05
vs. the other two treatment regimens. Reproduced with permission
from [30].
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plasma potassium in normal subjects receiving a low physio-
logic dose (0.015 mg/kg/mm) of epinephrmne; the same dose did
not change plasma potassium in a group of hemodialysis pa-
tients, despite similar plasma epinephrine concentrations. Allon
and Shanklin [50] investigated the mechanism responsible for
the resistance to the potassium-lowering effect of epinephrine in
patients with end-stage renal disease. They noted that epineph-
rifle is a mixed alpha- and beta-agonist, such that its net effect
on plasma potassium reflects the relative effects of alpha- and
beta-adrenergic stimulation. A resistance to the potassium
lowering effect of epinephrine in dialysis patients may reflect an
imbalance between its alpha- and beta-adrenergic effects. To
test this hypothesis, hemodialysis patients and normal controls
received a graded infusion of epinephrine at three physiologic
doses (0.01 to 0.04 g/kg/min), in the absence or presence of
concurrent beta-blockade with propranolol. Infusion of epi-
nephrine alone (mixed alpha- and beta-stimulation) to normal
controls resulted in a slight decrease in plasma potassium at the
lowest physiologic dose (0.01 g/kg/min), and substantial (0.6
mmollliter) decrease at the highest dose (0.04 g&g/min) (Fig.
3A). In contrast, in dialysis patients the lowest dose of epineph-
rine actually produced a significant increase in plasma potas-
sium, whereas even the highest dose failed to decrease serum
potassium.
Epinephrine infusion during beta-blockade ("pure" alpha
effect) resulted in a dose-dependent increase in plasma potas-
sium (Fig. 3B), that was significantly greater in dialysis patients
than in controls (0.7 vs. 0.3 mmol/liter). When the beta-
adrenergic effect was calculated by subtracting the "pure"
alpha effect from the total effect (epinephrine alone), there was
a similar dose-dependent decrease in plasma potassium in both
experimental groups (Fig. 3C). Moreover, epinephrine during
alpha-blockade with phentolamme ("pure" beta effect) pro-
duced comparable decreases in plasma potassium in both
experimental groups [50]. This set of observations suggests that
the potassium-lowering effect of epinephrine is blunted in
dialysis patients due to an enhanced aipha-adrenergic effect.
Fig. 3. Changes in serum potassium concentration (means SE) from
baseline during the infusion of intravenous epinephrine at three doses
in normal controls (•), hemodialysis patients (s), and renal transplant
patients () (serum creatinine <2 mg/dl). A. The effect of epinephrine
alone (alpha plus beta adrenergic stimulation). B. The effect of epineph-
rine during beta blockade ("pure" alpha effect). C. The calculated pure
beta effect. The changes in potassium in A and B were significantly (P
<0.05) different in the dialysis patients, as compared with the controls
and transplant patients, Adapted with permission from reference [50].
1200 Al/on: Hyperkalemia in ESRD
B 15 30 45 60
Time, minutes
Fig. 2. Changes in plasma glucose after treatment with insulin +
glucose (solid squares), albuterol (open circles), and insulin + glucose
+ albuterol (solid circles). * P< 0.005 vs. baseline value P < 0.001
vs. insulin treatment + P < 0.01 vs. the other two treatment regimens.
Reproduced with permission from reference [30].
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Another study suggested impaired beta-adrenergic potassium
disposal in dialysis patients, as inferred from the blunted
potassium lowering response to inhaled albuterol [56]. The
potassium-lowering effect of epinephrine or beta-2 agonists also
appears to be quite variable among hemodialysis patients. In a
number of clinical studies a sizable minority (20 to 40%) of
hemodialysis patients have been refractory to the potassium-
lowering effect of high-dose (0.10 ttgIkgImin) epinephrine [67,
68] or beta-2 agonists [30, 64]. The clinical characteristics that
predict these resistant patients are not known. For this reason,
albuterol should always be given in conjunction with insulin in
the acute treatment of hyperkalemia in these patients.
Insulin may play a permissive role in the potassium-lowering
effect of epinephrine in end-stage renal disease. A recent study
in hemodialysis patients observed no significant change in
plasma potassium during the infusion of epinephrine alone;
when the same patients were pretreated with intravenous
insulin so as to double plasma insulin levels within the physio-
logic range (from 9 to 20 mU/liter), an acute potassium lowering
effect of epinephrine was evident [69]. Thus, fasting may
contribute to the resistance to the potassium lowering effect of
epinephrine in dialysis patients, whereas physiologic doses of
exogenous insulin appear to overcome this resistance.
Recent experiments by our laboratory documented a reversal
of the abnormal response to epinephrine in patients with
end-stage renal disease after a successful kidney transplant
(serum creatinine <2.0 mg/dl). The changes in potassium during
epinephrine infusion in the absence or presence of propranolol
were similar to those measured in normal controls (Fig. 3). One
patient was studied twice, first while on dialysis, and again two
months after a successful kidney transplant. Before transplan-
tation, epinephrine at 0.01, 0.02, and 0.04 g/kmin produced a
0.5, 0.5, and 0.6 mmol/liter increase in plasma potassium,
respectively; two months after transplantation, the respective
changes in plasma potassium were +0.05, —0.2, and —0.6
mmol!liter.
Effect of aldosterone on extrarenal potassium disposal
The role of aldosterone in enhancing renal excretion of
potassium is firmly established [70, 71]. Aldosterone concentra-
tions are elevated in response to a high dietary potassium
intake, as well as in many patients with chronic renal failure [72,
73]. When this adaptive mechanism is blocked, either by
intrinsic kidney disease or by exogenous drugs, a positive
potassium balance results. As a result, patients with hy-
poreninemic hypoaldosteronism frequently develop hyperkale-
mia in the setting of mild renal insufficiency [74].
It is less clear whether aldosterone has a physiologic role in
the regulation of extrarenal potassium disposal. Although
plasma aldosterone levels are elevated by an acute potassium
load [38, 72], this acute increase does not appear to have a
physiologic role in the disposal of the potassium load. Acute
adrenalectomy did not impair the disposal of an acute potas-
sium load in rats [75, 76]. Other studies clearly demonstrated an
impairment of the tolerance of an acute potassium load by an
acute adrenalectomy [77—79]; however, this defect was not
affected by acute exogenous aldosterone or corticosteroids, and
was corrected by acute epinephrine administration [77]. Simi-
larly, in normal humans the acute suppression of aldosterone
synthesis by aminoglutethimide does not affect the tolerance of
an acute potassium load [38]. Finally, acute DOCA administra-
tion to chronically adrenalectomized rats does not enhance the
disposal of an acute potassium load [75].
There is conflicting evidence about the chronic role of aldo-
sterone in extrarenal potassium disposal. Chronic dietary po-
tassium loading is associated with chronic elevations of plasma
aldosterone. Alexander and Levinsky [75] found that rats
maintained chronically on a high potassium diet had enhanced
tolerance of an acute potassium load, associated with aug-
mented urinary potassium excretion. The protective effect of
chronic potassium loading was present even in acutely nephrec-
tomized rats, suggesting enhanced extrarenal potassium dis-
posal. The beneficial effect of a high potassium diet on the
extrarenal tolerance of an acute potassium load was abolished
by chronic adrenalectomy, and restored by chronic DOCA
administration. These observations suggest that chronic miner-
alocorticoid excess enhances, and chronic mineralocorticoid
deficiency impairs, extrarenal potassium disposal of an acute
potassium load. The beneficial effect of chronic potassium
loading on extrarenal potassium disposal has been supported by
additional studies [80, 81]. Dietary sodium restriction, another
maneuver that chronically elevates plasma aldosterone, also
enhances extrarenal tolerance of an acute potassium load [75].
Other investigators have failed to confirm a protective effect of
chronic dietary potassium loading or chronic sodium restriction
on the extrarenal tolerance of an acute potassium load [82, 83].
If aldosterone enhances intracellular uptake of potassium, this
should manifest as an increase in intracellular potassium con-
tent of skeletal muscle. In agreement with this prediction,
chronic aldosterone administration to dogs increases the pro-
portion of total exchangeable potassium that is intracellular [84,
85].
Because of the stimulatory effect of aldosterone on renal
potassium excretion, chronic aldosterone excess results in a
negative potassium balance, and chronic aldosterone deficiency
results in a positive potassium balance. It is difficult to deter-
mine, therefore, whether the effect of aldosterone on extrarenal
potassium tolerance is direct, or mediated by a change in total
body potassium. Studies in anephric individuals may help to
resolve this issue. Sugarman and Brown [86] evaluated the
effect of chronic (60 hour) mineralocorticoid inhibition with
spironolactone or chronic exogenous administration of DOCA
on extrarenal potassium disposal in hemodialysis patients main-
tained on a fixed diet. The disposal of an acute potassium load
was impaired by chronic spironolactone therapy, and enhanced
by chronic DOCA administration. In contrast, chronic (60 hour)
disposal of dietary potassium, as estimated from the volume of
distribution, was not affected by either maneuver. The authors
concluded that in dialysis patients aldosterone protects against
hyperkalemia following an acute potassium load. Taken to-
gether, balance studies in animals and humans suggest a phys-
iologic role for aldosterone in promoting extrarenal potassium
disposal [84—86]. However, further research is needed to clarify
this controversial area.
In addition to its stimulation of renal potassium secretion,
there is convincing evidence for a role of aldosterone in
stimulating intestinal potassium secretion. Like other cells,
colonic mucosal cells have Na-K-ATPase activity which results
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in potassium secretion into the stool. The activity of this
enzyme is increased by a high potassium diet; this adaptation is
absent in chronically adrenalectomized rats, and is restored by
aldosterone administration [87]. Exogenous mineralocorticoids
increase fecal potassium excretion in normal dogs and humans
[88, 89]. Colonic potassium secretion is increased in animals
and patients with chronic renal failure [90—94], an adaptive
mechanism that helps to prevent a positive potassium balance.
This adaptive change in renal failure is associated with an
increase in Na-K-ATPase activity in colonic mucosal cells [91].
It is not clear, however, that aldosterone contributes to en-
hanced colonic potassium secretion in patients with chronic
renal failure. In a recent clinical study neither exogenous
mineralocorticoid administration nor spironolactone therapy
affected fecal potassium excretion in hemodialysis patients [86].
Effect of bicarbonate on extrarenal potassium disposal
For many years bicarbonate has been routinely advocated for
the acute treatment of hyperkalemia in patients with acute renal
failure or end-stage renal disease. The most recent editions of
three major nephrology textbooks uniformly advocate bicar-
bonate therapy for the acute treatment of severe hyperkalemia
in dialysis patients, stating that a potassium-lowering effect of
bicarbonate starts within 30 minutes [2, 95, 96]. Moreover, in a
recent survey of 63 directors of nephrology training programs,
intravenous sodium bicarbonate was advocated by the majority
of respondents as the first choice of therapy [97]. Such an
overwhelming consensus about the utility of bicarbonate ther-
apy is surprising in view of the conflicting experimental evi-
dence regarding this recommendation.
Changes in serum potassium during acute acid-base changes
are quite variable [98]. A number of experimental studies in
bilaterally nephrectomized cats, dogs, and rabbits have demon-
strated that mineral (inorganic) metabolic acidosis acutely (in 2
to 4 hours) increases plasma potassium [99—102]. In contrast,
acute organic (lactic) acidosis has no effect on plasma potas-
sium in anephric cats [100]. Surprisingly, there are no reported
studies evaluating the acute effect of metabolic acidosis on
plasma potassium in patients with end-stage renal disease.
Given the acute rise in plasma potassium with inorganic
metabolic acidosis, one might predict that the administration of
sodium bicarbonate should acutely lower plasma potassium. In
fact, the published literature does not provide a conclusive
answer. The effect of bicarbonate administration on extrarenal
potassium disposal is difficult to interpret in animals with intact
kidneys, due to the stimulation of urinary potassium excretion
[103]. Animal studies utilizing acute (1 to 3 hours) sodium
bicarbonate infusions after bilateral nephrectomy have ob-
served a variable response. In two dog studies the plasma
potassium decreased significantly [102, 104]; in contrast, two
studies in rabbits and cats observed no significant change in
plasma potassium [100, 101]. It is not clear from the literature
whether the effect of acute sodium bicarbonate administration
on plasma potassium differs in the setting of established meta-
bolic acidosis, as compared with the effect in animals with a
normal acid-base status. A retrospective study in four hyper-
kalemic, uremic patients suggested that sodium bicarbonate
administration lowered serum potassium substantially within a
few hours [105]. In a study frequently cited to support the
efficacy of bicarbonate therapy, Fraley and Adler [106] admin-
istered sodium bicarbonate, 400 to 600 mmol over 16 to 24
hours, to a group of hyperkalemic patients and observed a 0.6
mmol!liter decrease in plasma potassium after four to six hours,
and a 1.6 mmollliter decrease at 16 to 24 hours. It was not
reported, however, whether a meaningful reduction of plasma
potassium occurred within the first two hours, a timeframe
useful for the acute treatment of hyperkalemia prior to initiation
of dialysis.
Three recent prospective clinical studies have questioned the
usefulness of bicarbonate for the acute therapy of hyperkalemia
in hemodialysis patients. Blumberg et al [31] showed no change
in plasma potassium during one hour of administration of about
200 mmol of bicarbonate to hemodialysis patients. This was
true regardless of whether hypertonic or isotonic bicarbonate
was provided. Guttierrez et a! [107] found no decrease in
plasma potassium for the first three hours after bicarbonate
administration, despite significant increases in plasma bicarbon-
ate and pH. In a third study, hemodialysis patients received a
six hour infusion of bicarbonate; a significant decrease in
plasma potassium was not evident until four hours after starting
the infusion [108] (Fig. 4). Moreover, during the first hour of
bicarbonate therapy most hyperkalemic dialysis patients did not
manifest any improvement in their electrocardiographic abnor-
malities. Thus, although sodium bicarbonate decreases plasma
potassium during prolonged administration, it does not appear
to be reliable in the acute treatment of hyperkalemia. None of
these studies utilized patients with severe metabolic acidosis,
so it is still possible that bicarbonate therapy may be rapidly
effective in treatment of hyperkalemia in that subset of hemo-
dialysis patients. Of course, in patients with severe metabolic
acidosis, bicarbonate administration is indicated even in the
absence of hyperkalemia.
Acute treatment of hyperkalemin
The definitive treatment of severe hyperkalemia in a patient
with end-stage renal disease is to remove potassium from the
body. Hemodialysis is the most effective regimen for the acute
lowering of plasma potassium concentration [31]. However,
because there is often a two to three hour delay between
recognition of the hyperkalemia and institution of dialysis, a
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Fig. 4. Changes in plasma potassium during intravenous infusion of
bicarbonate in hemodialysis patients. Values represent means SE.
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Table 1. Treatment and prevention of hyperkalemia
Acute treatment of severe hyperkalemia
Stabilize myocardium
Calcium gluconate
Shift potassium into the cells
Intravenous insulin
Nebulized albuterol
Sodium bicarbonate (?)
Remove potassium from the body
Sodium polystyrene sulfonate (Kayexalate)
Hemodialysis
Prevention of hyperkalemia
Dietary potassium restriction
Avoidance of beta-blockers
Intravenous insulin-plus-dextrose during fasting
Avoidance of constipation
Avoidance of converting enzyme inhibitors
Calcium channel blockers (?)
number of temporizing measures are employed to prevent
cardiotoxicity from hyperkalemia (Table 1). The most immedi-
ate measure is the administration of intravenous calcium (10 to
20 ml of 10% calcium gluconate). Although this has no effect on
plasma potassium, it has an immediate beneficial effect on the
ventricular rhythm. The effect of calcium gluconate is short-
lived, lasting no longer than 30 minutes.
The goal of subsequent therapeutic maneuvers is to shift
potassium from the extracellular to the intracellular fluid com-
partment. The beneficial effect of insulin in this regard is firmly
established, and is observed within 15 minutes. Dextrose must
be administered with insulin to prevent the predictable hypo-
glycemia. Ten units of regular insulin and 50 ml of 50% dextrose
are given as an intravenous bolus. Because of the high inci-
dence of late hypoglycemia [30], this should be followed by a
continuous infusion of 10% dextrose at 50 ml/hr. Nebulized
albuterol, 20 mg dissolved in 4 ml of saline and inhaled over 10
minutes, is given after the insulin to achieve an additive
potassium-lowering effect. This dose of albuterol is eightfold
higher than the clinical dose usually prescribed in the acute
treatment of asthma. Because only the systemically absorbed
drug is effective in promoting extrarenal potassium disposal, the
usual therapeutic dose (2.5 mg) is inadequate for the acute
treatment of hyperkalemia. A decrease in plasma potassium
occurs within 30 minutes of therapy with nebulized albuterol.
As discussed previously, the potassium-lowering effect of bi-
carbonate is quite variable, and may be delayed as long as four
hours. Therefore, it is not reliable in the acute management of
hyperkalemia. Sodium bicarbonate therapy is still indicated,
however, in chronic renal failure patients with severe acidosis
(pH <7.20) regardless of the levels of plasma potassium.
Finally, sodium polystyrene sulfonate (Kayexalate) with sor-
bitol can be used to increase excretion of potassium in the gut
[109, 110]. The onset of action of Kayexalate is slower than that
of insulin or nebulized albuterol, starting one to two hours after
drug administration. Each gram of Kayexalate removes 0.5 to
1.0 mmol of potassium, in exchange for an equal amount of
sodium. Because intestinal potassium exchange occurs primar-
ily in the ileum and colon, Kayexalate administration by reten-
tion enema is preferable to the oral route in acute symptomatic
hyperkalemia. A dose of 50 g Kayexalate in a sorbitol suspen-
sion is given by retention enema at four to six hour intervals.
Although the use of Kayexalate with sorbitol is generally
regarded as safe, its oral or rectal administration may rarely
produce intestinal necrosis [111—113]. Experimental evidence
suggests that the necrosis is caused by sorbitol, rather than by
Kayexalate [111].
Prevention of hyperkalemia
Extrarenal potassium disposal in uremia
Despite the absence of meaningful renal excretion of potas-
sium in hemodialysis patients, most hemodialysis patients do
not develop severe hyperkalemia in the interdialytic period. In
one study, only 10% of hemodialysis patients had predialysis
plasma potassium concentrations >6.0 mmol/liter [114]. The
efficiency of extrarenal potassium disposal in defending against
hyperkalemia is evident if one considers the fate of a meal
containing 35 mmol of potassium ingested by a 70 kg dialysis
patient. Assuming that extracellular fluid volume is 20% of total
body weight (14 liters), and that the ingested potassium was
distributed exclusively in this compartment, one would antici-
pate an acute 2.5 mmol/liter rise in plasma potassium, a
potentially lethal event. Clearly, an efficient extrarenal potas-
sium disposal mechanism prevents life-threatening hyperkale-
mia after the ingestion of dietary potassium.
Studies in both animals with experimental renal failure and
patients on dialysis have observed a defect in extrarenal dis-
posal of potassium. This defect has been inferred by measuring
changes in plasma potassium after an acute potassium load.
Rats with 3/4 nephrectomy developed more severe hyperkale-
mia after an oral potassium load than did control rats, despite
similar urinary potassium excretion in both groups [13]. More-
over, Na-K-ATPase activity in skeletal muscle fibers, as in-
ferred from ouabain-sensitive rubidium uptake, was signifi-
cantly lower in uremic than control rats. Two clinical
investigations found a substantially greater rise in plasma
potassium following an oral potassium load (0.25 mmol/kg) in
hemodialysis patients as compared to normal controls [115,
116]. In one study the maximal increase in plasma potassium
was 0.93 and 0.52 mmol/liter in dialysis patients and normal
controls, respectively. In the second study the corresponding
increases were 1.06 and 0.39 mmollliter, respectively. In both
studies the magnitude of renal excretion in the control subjects
could not account for the difference in the hyperkalemic re-
sponse. The defect in extrarenal potassium disposal associated
with uremia persists even when the potassium load is accom-
panied by oral glucose, so as to stimulate endogenous insulin
secretion [13, 115, 117].
The defect in extrarenal potassium disposal in chronic renal
failure is most likely due to an impairment in the Na-K pump.
The mechanism by which uremia affects the Na-K pump is not
established. Some factors that may play a role include volume
overload, metabolic acidosis, a putative endogenous ouabain-
like substance, thyroxine deficiency, and hyperparathyroidism
[23].
Role of endogenous insulin and catecholamines
Whereas it is well established that both endogenous insulin
and epinephrine stimulate potassium shifts into the intracellular
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fluid compartment, it is less clear whether hyperkalemia in-
creases circulating concentrations of insulin or epinephrine.
Confirmation of such an effect would establish an attractive
negative feedback system whereby an acute rise in plasma
potassium stimulates the release of insulin or epinephrine,
which in turn corrects the hyperkalemia by stimulating extra-
renal potassium shifts [118]. Potassium stimulates in vitro
insulin secretion by the isolated perfused pancreas or islet cell
suspensions from rat or rabbit [119—122], however, this effect
has been observed only at extreme degrees of hyperkalemia (>8
mmollliter). A number of in vivo studies in normal or uremic
dogs have demonstrated substantial stimulation of insulin levels
after an acute potassium load [72, 123—125]. Moreover, potas-
sium-induced insulin secretion was augmented in uremic dogs
[72]. In contrast, there is little evidence in humans for direct
stimulation of insulin by acute changes of potassium within the
physiologic range. A number of studies in which normal sub-
jects received an acute potassium load found no measurable
stimulation of plasma insulin [115, 126—128]. One study de-
scribed a small (about 6 mU/liter) stimulation of insulin by
potassium, but only in subjects maintained on a potassium
restricted diet for several days [129]. It is unlikely, however,
that a change in plasma insulin of this small magnitude is
sufficient to enhance extrarenal potassium disposal in normal
controls [130]. Infusion of potassium chloride in dialysis pa-
tients, so as to raise the plasma potassium by 1.5 mmol/liter, did
not increase plasma insulin levels [131]. It is still conceivable
that an oral potassium load could stimulate an increase in
endogenous insulin secretion that would not be detected sys-
temically because of catabolism of insulin in the portal circula-
tion. However, an increase in C-peptide would be anticipated
under such circumstances, and this was not observed in two
studies in hemodialysis patients [115, 116].
Although it is doubtful that an acute potassium load directly
stimulates insulin secretion in humans, this does not diminish
from the physiologic role of this hormone in promoting extra-
renal potassium disposal. Even the low physiologic insulin
concentrations present during fasting protect against hyperka-
lemia. Infusion of normal fasting rats, dogs, and humans with
somatostatin, to suppress basal insulin secretion, results in an
acute increase in plasma potassium [13, 132]. The hyperkalemic
effect of somatostatin in fasting dogs is prevented by simulta-
neous infusion of insulin at low physiologic doses [132]. Circu-
lating insulin during fasting may be particularly critical in
chronic renal failure. This was suggested by the observation
that somatostatin infusion results in a greater increase of plasma
potassium in rats with renal failure, as compared to control rats
[13]. In a recent report, administration of an oral glucose load
lowered the plasma potassium in a nondiabetic dialysis patient.
When the same glucose load was repeated during somatostatin
infusion, so as to prevent an increase in plasma insulin, pro-
found hyperkalemia developed [1331.
Dietary potassium is not generally ingested alone, but rather
in conjunction with food containing carbohydrates. Exogenous
glucose directly stimulates insulin release, and has been shown
to acutely lower plasma potassium in nondiabetic individuals.
Studies in normal and uremic rats and humans have demon-
strated that the rise in plasma potassium after a potassium load
is blunted substantially when oral glucose is provided concom-
itantly [13, 115]. Carbohydrate feeding also increases sympa-
Fig. 5. Changes in plasma potassium from baseline following the
administration of an oral potassium load alone or in combination with
oral glucose to dialysis patients and normal subjects. A. Studies in the
absence of propranolol, and B shows studies in the presence of
propranolol. Values represent means SE. Solid symbols denote
hemodialysis (HD) patients; open symbols are normal controls; solid
lines are KCI without glucose; broken lines are KC1 with glucose. The
increase in plasma potassium was significantly less (P < 0.01) after KCI
+ glucose, as compared with KC1 alone, both in the absence or
presence of propranolol, both in hemodialysis patients and in normal
controls. Reproduced with permission from reference [1151.
thetic nervous system activity [134, 135], and beta-adrenergic
stimulation enhances extrarenal potassium disposal. Thus, the
enhanced tolerance of a potassium load during concomitant
glucose administration could be due to increased beta-adrener-
gic stimulation, independent of the change in insulin. However,
the magnitude of protective effect of exogenous glucose against
hyperkalemia after a potassium load is similar in the absence or
presence of beta-blockade [115] (Fig. 5), suggesting that stimu-
lation of insulin is the primary mechanism whereby exogenous
glucose defends against hyperkalemia.
The protective effect of endogenous insulin in the prevention
of fasting hyperkalemia in patients with end-stage renal disease
is also illustrated by a comparison of patients on continuous
ambulatory peritoneal dialysis and on hemodialysis. Absorption
of glucose from the dialysate stimulates endogenous insulin
secretion in fasting pentoneal dialysis patients [136, 137], which
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should enhance extrarenal potassium disposal. As a result, the
incidence of severe hyperkalemia (serum potassium >6.0
mmol/liter) is 0.6% in peritoneal dialysis patients, significantly
lower than the 10% incidence in hemodialysis patients [114].
An acute potassium load does not increase plasma epineph-
rifle or norepinephrine levels in humans [126, 1271. Moreover,
fasting epinephrine and norepinephrine levels are similar in
patients with end-stage renal disease and in normal controls
[51]. Nevertheless, circulating catecholamines contribute to
extrarenal disposal of a potassium load. The physiologic impor-
tance of the beta-adrenergic system in the defense against
hyperkalemia has been highlighted by several well-designed
studies. Thus, during infusion of potassium chloride to normal
animals or humans the administration of epinephrine attenuates
the rise in plasma potassium concentration, whereas beta-2
selective blockers or nonselective beta-blockers enhance the
degree of hyperkalemia [126, 127, 138, 139]. Similar effects of
beta-blockade have been observed in patients with end-stage
renal disease. Predialysis serum potassium was increased by 0.7
mmollliter in dialysis patients maintained on a constant diet and
treated for 10 days with propranolol, but not affected by the
selective beta-i antagonist, atenolol [140]. Vigorous exercise is
another maneuver that promotes hyperkalemia by causing a
shift of potassium from the muscles into the extracellular
compartment. Pretreatment with the nonselective beta-blocker,
propranolol, worsens exercise-induced hyperkalemia in normal
subjects [59]. Similarly, propranolol, but not the beta-l selec-
tive antagonist, metoprolol, augments the hyperkalemic effect
of exercise in hemodialysis patients [141].
Role of fasting
The progressive increase in plasma potassium during the
interdialytic period is usually attributed to dietary intake of
potassium that cannot be excreted. It is not well appreciated,
however, that nondiabetic hemodialysis patients are prone to
develop hyperkalemia when they are fasted. This phenomenon
was highlighted by Gifford et al [51], who observed a 0.5
mmol/liter increase in plasma potassium in hemodialysis pa-
tients fasted for 26 hours, in contrast to normal controls, who
had no significant change. Solomon and Dubey [142] evaluated
the change in plasma potassium in hemodialysis patients during
a 24 hour period with a fixed feeding schedule. Not surprisingly,
plasma potassium increased significantly during the observation
period; however, most of the increase occurred during fasting
(between dinner and breakfast). Fasting hyperkalemia may be a
serious iatrogenic problem whenever hemodialysis patients are
fasted in preparation for surgery or a diagnostic procedure.
Given the known stimulatory effect of insulin on extrarenal
potassium disposal, we recently evaluated whether a continu-
ous infusion of physiologic doses of insulin (with the addition of
dextrose) could prevent fasting hyperkalemia in nondiabetic
hemodialysis patients. During an 18 hour fast, the patients
developed a mean 0.6 mmol/liter increase in plasma potassium.
This increase was completely abolished by a continuous infu-
sion of insulin and glucose at rates that doubled plasma insulin
levels within the physiologic range (from 9 to 20 mU/liter) [691
(Fig. 6). Because exogenous glucose stimulates the endogenous
secretion of insulin in nondiabetic patients, the effect of dex-
trose infusion without insulin on fasting hyperkalemia was
evaluated. This protocol resulted in a rise in plasma potassium
0 6 12 18
Hours of fasting
Fig. 6. Serial plasma potassium and insulin concentrations during an
18 hour fast in hemodialysis patients in the absence (solid squares) or
presence (open squares) of a continuous physiologic infusion of insulin
(1 U/hr) with dextrose (5 g/hr). Values represent means SE for 10
patients. A. * P < 0.05, ** P < 0.01 vs. the value at 6 hours of fasting;
B. + P < 0.01 vs. the corresponding value in the control experiment.
Reproduced with permission from reference [69].
that was intermediate between that observed in the absence of
an infusion and that observed during the infusion of insulin with
dextrose [69].
Role of PTH in extrarenal potassium disposal
Recent experimental evidence suggests a contributory role
for PTH in the pathogenesis of a number of functional abnor-
malities in chronic renal failure, including the defect in extra-
renal potassium disposal. In acutely nephrectoniized rats exog-
enous PTH impairs extrarenal potassium disposal [143].
Conversely, in rats with chronic renal failure and secondary
hyperparathyroidism, parathyroidectomy enhances the toler-
ance of an acute potassium load [144]. How PTH affects
extrarenal potassium disposal remains to be elucidated. Studies
with pancreatic islet cells from renal failure rats have demon-
strated higher resting levels of cytosolic calcium, lower ATP
content, and decreased activities of Ca2-ATPase and Na-K-
ATPase, as compared with islet cells from control animals [122,
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145—147]. All these physiologic and biochemical abnormalities
were corrected by parathyroidectomy or by administration of
verapamil to parathyroid-intact uremic rats. Assuming that
these observations are representative of the changes in skeletal
muscle cells in chronic renal failure, the following hypothesis
may explain the role of PTH in the defect in extrarenal
potassium disposal. Elevated PTH levels produce a chronic
increase in cytosolic calcium levels [148, 149]. This, in turn,
inhibits mitochondrial oxidation, and its generation of ATP
[150, 151]. The low cellular ATP levels inhibit Na-K-ATPase
activity [152], thereby inhibiting potassium shifts into the intra-
cellular fluid compartment. Prevention of the chronic increase
in cytosolic calcium, either by parathyroidectomy or by a
calcium channel blocker, would raise skeletal muscle Na-K-
ATPase activity, thereby enhancing extrarenal potassium dis-
posal in chronic renal failure.
Because PTH receptors have not been demonstrated in
skeletal muscle, it is not clear how PTH might affect cytosolic
calcium in these cells. Moreover, an effect of PTH on extrarenal
potassium disposal has not been reported in patients with
end-stage renal disease. A recent clinical study reported that
short-term therapy with the calcium channel blocker, diltiazem
blunted the increase in plasma potassium during a 24-hour
observation period in dialysis patients who were on a fixed diet,
suggesting that elevated cytosolic calcium levels may impair
extrarenal potassium disposal [142]. Clearly, much more re-
search is required to evaluate the role of PTH on potassium
homeostasis in dialysis patients before any firm conclusions can
be made.
Specific measures for prevention of hyperkalemia in dialysis
patients
A number of measures may be useful in minimizing the
occurrence of hyperkalemia in dialysis patients (Table 1).
Because hemodialysis patients have negligible renal excretion
of potassium, the majority of dietary potassium ingested in the
interdialytic period accumulates in the body. Thus, it seems
prudent to restrict dietary potassium intake. Given the critical
importance of extrarenal potassium disposal in the defense
against hyperkalemia, maneuvers that interfere with this pro-
cess should be avoided. Specifically, one should avoid the use
of beta-blockers in dialysis patients. If beta-blockers must be
used, beta-i blockers should be used preferentially, recognizing
that the selectivity is lost at higher doses.
One should anticipate the development of hyperkalemia
when hospitalized hemodialysis patients are fasted in prepara-
tion for surgery or a diagnostic procedure, or when they
experience protracted nausea and vomiting. A continuous infu-
sion of insulin with dextrose can prevent this complication (add
20 units of regular insulin to a liter of 10% dextrose, and infuse
at 50 mllhr) [69]. This prophylactic regimen may produce
hypoglycemia in some patients, mandating periodic evaluation
of fingerstick glucose concentration. Although dextrose alone
may be adequate, by stimulating endogenous insulin secretion,
it may be less efficacious than the combined infusion of insulin
with dextrose in preventing fasting hyperkalemia. Of course, in
diabetic dialysis patients the combined regimen would be man-
datory.
Given the enhanced role of colonic potassium secretion in
chronic renal failure, avoidance of constipation seems prudent.
In patients with residual renal function endogenous aldosterone
helps to maximize urinary potassium excretion; therefore,
converting enzyme inhibitors, which decrease aldosterone pro-
duction, should be avoided. Finally, calcium channel blockers
may be useful in the prevention of hyperkalemia in dialysis
patients [142], although further clinical studies will be required
to evaluate this possibility.
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